Italy's CBD Twist: A Step Back Amidst Booming Global Green Gold?
Italy's CBD Twist: A Step Back Amidst Booming Global Green Gold?
The Italian government has controversially reclassified cannabidiol (CBD) as a narcotic. This latest development is another twist in the ongoing regulatory saga around the hemp-derived compound in the European country.
这个 意大利政府 有争议地将大麻二酚（CBD）重新归类为 麻醉品。这一最新进展是欧洲国家围绕大麻衍生化合物的持续监管传奇的又一转折。
Despite the global CBD market forecasting a growth from 4.9 Billion in 2022 to 47.22 billion by 2030, Italy seems to be taking a step back. The current anticipated CAGR for the industry stands at 21.2%.
尽管全球CBD市场预测到2030年将从2022年的49亿个增长到472.2亿美元，但意大利似乎正在退后一步。该行业目前预期的复合年增长率为21.2％。
See Also: Italy Sparks Controversy by Reclassifying Oral CBD as a Narcotic: Uncertainty and Debate in the European Market
另请参阅： 意大利将口服CBD重新归类为麻醉品，引发争议：欧洲市场的不确定性和争论
Background
背景
Historically, the regulatory position in Italy has been inconsistent.
从历史上看，意大利的监管状况一直前后矛盾。
In 2020, a decree was issued tagging CBD as a narcotic, only to be repealed shortly after. A subsequent 2021 decree met the same fate, with the regional court of Lazio advising alignment with EU regulations.
2020年，发布了一项法令，将CBD标记为麻醉品，但不久之后才被废除。随后的2021年法令遇到了同样的命运，拉齐奥地区法院建议与欧盟法规保持一致。
It's notable that in 2020, the European Commission, applicable to all EU member states, ruled that CBD shouldn't be classified as a narcotic. However, the Italian Ministry of Health has chosen to diverge from this stance. Their latest announcement, published in the Official Gazette, becomes effective from September 21, 2023.
值得注意的是，2020年，适用于所有欧盟成员国的欧盟委员会裁定，不应将CBD归类为麻醉品。但是，意大利卫生部选择偏离这一立场。他们的最新公告发布在《官方公报》上，生效日期为 2023年9月21日。
According to Hemp Today, key industry stakeholders, including Canapa Sativa Italia and Federcanapa, are publicly opposing this move, warning of its potential negative impact on businesses and the local CBD market. Expert neuropharmacologist, Viola Brugnatelli, underscored the economic repercussions, while legal expert Carlo Alberto Zaina urged industry unity against this decree.
据《今日大麻》报道，包括Canapa Sativa Italia和Federcanapa在内的主要行业利益相关者公开反对这一举动，并警告其可能对企业和当地CBD市场产生负面影响。神经药理专家维奥拉·布鲁尼亚泰利强调了经济影响，而法律专家卡洛·阿尔贝托·扎伊纳则敦促行业团结起来反对该法令。
Despite these changes, Italy's medical cannabis market, which has witnessed steady growth over recent years, continues to source cannabis primarily from the Netherlands, Canada, Denmark, and Germany, with Aurora Cannabis Inc. (NASDAQ:ACB) among the top suppliers since 2019.
尽管发生了这些变化，但近年来稳步增长的意大利医用大麻市场继续主要从荷兰、加拿大、丹麦和德国采购大麻， 奥罗拉大麻公司 纳斯达克股票代码：ACB）自2019年以来一直位居顶级供应商之列。
Cannabis Capital Conference In Chicago
芝加哥大麻资本会议
If you are interested in knowing more about the latest cannabis developments around the globe, consider joining us at the Benzinga Cannabis Capital Conference in Chicago this September 27-28.
如果您有兴趣进一步了解最新的大麻发展 在全球各地，可以考虑加入我们 本辛加大麻资本会议 在 今年 9 月 27 日至 28 日的芝加哥。
Get your tickets today before prices go up and secure a spot at the epicenter of cannabis investment, retail, culture, and branding. All information is available on bzcannabis.com
在价格上涨之前立即购买门票，在大麻投资、零售、文化和品牌的中心占有一席之地。 所有信息都可在 bzcannabis.com 上找到
Read Next: Italians To Enjoy Medical Marijuana Offerings From One Of The Biggest Cannabis Companies In The World
继续阅读： 意大利人将享受世界上最大的大麻公司之一提供的医用大麻产品
Image by El Planteo
图片由 El Planteo